Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is conducting a study titled A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies. The study aims to evaluate the safety and effectiveness of ABBV-319, an investigational drug, in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This research is significant as it targets aggressive and common forms of B-cell malignancies.
The intervention being tested is ABBV-319, administered intravenously. It is designed to treat patients with relapsed or refractory DLBCL, FL, and CLL by determining appropriate dosing and assessing changes in disease activity.
The study is interventional and non-randomized, with a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment. The study includes a dose escalation phase followed by a dose expansion phase.
The study began on April 26, 2023, and is currently recruiting participants. The last update was submitted on June 24, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This clinical study update could influence AbbVie’s stock performance by showcasing its commitment to advancing cancer treatments. Positive outcomes may boost investor confidence, while the competitive landscape in oncology could also affect market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.